Lipid profiles and the risk of endometrial cancer in the Swedish amoris study

International Journal of Molecular Epidemiology and Genetics

Volumn 3, Issue 2, 2012, Pages 122-133

  Seth, Divya ^a,b   Garmo, Hans ^a,c   Wigertz, Annette ^c   Holmberg, Lars ^a,c   Hammar, Niklas ^d,e   Jungner, Ingmar ^d   Lambe, Mats ^c,d   Walldius, Göran ^d   van Hemelrijck, Mieke ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HARVARD COLLEGE   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

Endometrial cancer; Lipid profiles; Risk factor; Swedish AMORIS study

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CANCER RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; RISK FACTOR; SWEDEN; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84861770961     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Schmandt RE, Iglesias DA, Co NN and Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 2011; 205: 518-525.
2. Renehan AG, Tyson M, Egger M, Heller RF and Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
3. MacDonald PC, Edman CD, Hemsell DL, Porter JC and Siiteri PK. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without en-dometrial cancer. Am J Obstet Gynecol 1978; 130: 448-455.
4. Savona-Ventura C, Grima S and Buttigieg GG. Metabolic carcinogenesis in the Maltese population. Exp Clin Endocrinol Diabetes 2009; 117: 78-82.
5. Yoon M. The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res 2009; 60: 151-159.
6. Lindemann K, Vatten LJ, Ellstrom-Engh M and Eskild A. Serum lipids and endometrial cancer risk: results from the HUNT-II study. Int J Cancer 2009; 124: 2938-2941.
7. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjonneland A, Olsen A, Overvad K, Jakobsen MU, Chajes V, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Lukanova A, Boeing H, Pischon T, Trichopoulou A, Christina B, Trichopoulos D, Palli D, Berrino F, Panico S, Tumino R, Sacerdote C, Gram IT, Lund E, Quiros JR, Travier N, Martinez-Garcia C, Larranaga N, Chirlaque MD, Ardanaz E, Berglund G, Lundin E, Bueno-de-Mesquita HB, van Duijnhoven FJ, Peeters PH, Bingham S, Khaw KT, Allen N, Key T, Ferrari P, Rinaldi S, Slimani N and Riboli E. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007; 14: 755-767.
8. Swanson CA, Potischman N, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Hoover RN and Brinton LA. Endometrial cancer risk in relation to serum lipids and lipoprotein levels. Cancer Epidemiol Biomarkers Prev 1994; 3: 575-581.
9. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W and Steiner E. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998; 44: 1641-1649.
10. Jungner I, Walldius G, Holme I, Kolar W and Steiner E. Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females. Int J Clin Lab Res 1992; 21: 247-255.
11. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-2033.
12. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I and Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control 2011; 22: 1163-1171.
13. Mattsson B and Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984; 23: 305-313.
14. Van Hemelrijck M, Garmo H, Binda E, Hayday A, Karagiannis SN, Hammar N, Walldius G, Lambe M, Jungner I, Holmberg L. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes Control 2010;21:1657-67.
15. Van Hemelrijck M, Garmo H, Holmberg L, Wall-dius G, Jungner I, Hammar N, Lambe M. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011;117:2086-95.
16. Walldius G and Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy a review of the evidence. J Intern Med 2006; 259: 493-519.
17. Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF, Massana L, Mangas A, Hernandez Mijares A, Gonzalez-Santos P, Ascaso JF and Pedro-Botet J. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009; 5: 757-765.
18. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
19. Hinkula M, Pukkala E, Kyyronen P and Kauppila A. Grand multiparity and incidence of endo-metrial cancer: a population-based study in Finland. Int J Cancer 2002; 98: 912-915.
20. Janssen I, Powell LH, Crawford S, Lasley B and Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med 2008; 168: 1568-1575.
21. Bengtsson C, Lindquist O and Redvall L. Menstrual status and menopausal age of middle-aged Swedish women. A population study of women in Goteborg 1968-69 and 1974-75. Acta Obstet Gynecol Scand 1981; 60: 269-275.
22. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J and Albanes D. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Bio-markers Prev 2009; 18: 2814-2821.
23. Van Hemelrijck M, Garmo H, Holmberg L, Wall-dius G, Jungner I, Hammar N and Lambe M. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer 2011; 117: 2086-2095.
24. Van Hemelrijck M, Walldius G, Jungner I, Ham-mar N, Garmo H, Binda E, Hayday A, Lambe M and Holmberg L. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control 2011; 22: 1011-1019.
25. Van Hemelrijck M, Garmo H, Hammar N, Jung-ner I, Walldius G, Lambe M and Holmberg L. The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. Int J Cancer 2012; 130: 2118-2128.
26. Kark JD, Smith AH and Hames CG. The relationship of serum cholesterol to the incidence of cancer in Evans County, Georgia. J Chronic Dis 1980; 33: 311-332.
27. Williams RR, Sorlie PD, Feinleib M, McNamara PM, Kannel WB and Dawber TR. Cancer incidence by levels of cholesterol. JAMA 1981; 245: 247-252.
28. Wallace RB, Rost C, Burmeister LF and Pom-rehn PR. Cancer incidence in humans: relationship to plasma lipids and relative weight. J Natl Cancer Inst 1982; 68: 915-918.
29. Chawla A, Repa JJ, Evans RM and Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-1870.
30. Ota K, Ito K, Suzuki T, Saito S, Tamura M, Haya-shi S, Okamura K, Sasano H and Yaegashi N. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clin Cancer Res 2006; 12: 4200-4208.
31. Roberts-Thomson SJ. Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment. Immunol Cell Biol 2000; 78: 436-441.
32. Saidi SA, Holland CM, Charnock-Jones DS and Smith SK. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 2006; 5: 13.
33. van Raalte DH, Li M, Pritchard PH and Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 2004; 21: 1531-1538.
34. Holland CM, Saidi SA, Evans AL, Sharkey AM, Latimer JA, Crawford RA, Charnock-Jones DS, Print CG and Smith SK. Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets. Mol Cancer Ther 2004; 3: 993-1001.
35. Bjorge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, Rapp K, Ulmer H, Almquist M, Con-cin H, Hallmans G, Jonsson H, Stattin P and Engeland A. Metabolic syndrome and endo-metrial carcinoma. Am J Epidemiol 2010; 171: 892-902.
36. Friedenreich CM, Biel RK, Lau DC, Csizmadi I, Courneya KS, Magliocco AM, Yasui Y and Cook LS. Case-control study of the metabolic syndrome and metabolic risk factors for endo-metrial cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2384-2395.
37. Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, Franceschi S and La Vecchia C. Metabolic syndrome and endometrial cancer risk. Ann Oncol 2011; 22: 884-889.
38. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman M, Ferris RL, Kagan VE and Gabrilovich DI. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 2010; 16: 880-886.
39. Elwood JM, Cole P, Rothman KJ and Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst 1977; 59: 1055-1060.
40. Lambe M, Wuu J, Weiderpass E and Hsieh CC. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control 1999; 10: 43-49.
41. Valette A, Verine A, Varesi L and Boyer J. Effects of ethynyl estradiol and progesterone on triglyc-eride metabolism in the female rat. Endocrinology 1978; 103: 1647-1653.
42. Henderson BE and Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427-433.
43. Bonithon-Kopp C, Scarabin PY, Darne B, Mal-mejac A and Guize L. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int J Epidemiol 1990; 19: 42-48.
44. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V and Sacks FM. Effects of postmeno-pausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-1204.
45. Holzmann M, Jungner I, Walldius G, Ivert I, Nordqvist T and Östergren J. Apolipoproteins B and AI, standard lipid measures and incidence of myocardial infarction in men and women, with or without chronic kidney disease. Study IV in Thesis for doctorial degree (PhD). In: Holzmann M, editors. Renal insufficiency, mortality and myocardial infarction. Stockholm: Karolinska Institutet; 2008.